首页 > 最新文献

Transfusion and Apheresis Science最新文献

英文 中文
The practical use of artificial intelligence in Transfusion Medicine and Apheresis 人工智能在输血医学和血液透析中的实际应用
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-09-10 DOI: 10.1016/j.transci.2024.104001
Celine Anstey , David Ullman , Leon Su , Chuying Su , Chad Siniard , Sierra Simmons , Jesse Edberg , Lance A. Williams III

Background

Blood and plasma volume calculations are a daily part of practice for many Transfusion Medicine and Apheresis practitioners. Though many formulas exist, each facility may have their own modifications to consider. ChatGPT (Generative Pre-trained Transformer) provides a new and exciting pathway for those with no programming experience to create personalized programs to meet the demands of daily practice. Additionally, this pathway creates computer programs that provide accurate and reproducible outputs. Herein, we aimed to create a step-by-step process for clinicians to create customized computer programs for use in everyday practice.

Methods

We created a process of inputs to ChatGPT-40, which generated computer programming code. This code was copied and pasted into Notepad (and saved as a Python file) and Google Colaboratory to verify functionality. We validated the durability of our process by repeating it over a 5-day timeframe and by recruiting volunteers to reproduce our outputs using the suggested process.

Results

Computer code generated by ChatGPT-40 in response to our common language inputs was accurate and durable over time. The code was fully functional in both Python and Colaboratory. Volunteers reproduced our process and outputs with minimal assistance.

Conclusion

We analyzed the practical application of ChatGPT-40 and artificial intelligence (AI) to perform daily calculations encountered in Transfusion Medicine. Our results provide a proof of concept that people with no programming experience can create customizable solutions for their own facilities. Our future work will expand to the creation of comprehensive and customizable websites designed for each individual user.

背景血液和血浆容量计算是许多输血医学和无细胞疗法从业人员日常工作的一部分。虽然有很多公式,但每个机构都可能有自己的修改需要考虑。ChatGPT(生成式预训练变换器)为那些没有编程经验的人提供了一个全新的、令人兴奋的途径,让他们可以创建个性化的程序,以满足日常实践的需求。此外,这种方法创建的计算机程序还能提供准确且可重复的输出。在此,我们的目标是为临床医生创建一个循序渐进的流程,以创建用于日常实践的定制计算机程序。方法我们创建了一个向 ChatGPT-40 输入的流程,该流程可生成计算机编程代码。我们将这些代码复制并粘贴到记事本(并保存为 Python 文件)和谷歌实验室中,以验证其功能。我们在 5 天的时间内重复了这一过程,并招募志愿者使用建议的过程重现我们的输出结果,从而验证了这一过程的持久性。代码在 Python 和 Colaboratory 中都能正常运行。结论我们分析了 ChatGPT-40 和人工智能(AI)在执行输血医学日常计算中的实际应用。我们的结果提供了一个概念证明,即没有编程经验的人也可以为自己的设施创建可定制的解决方案。我们未来的工作将扩展到为每个用户创建全面的可定制网站。
{"title":"The practical use of artificial intelligence in Transfusion Medicine and Apheresis","authors":"Celine Anstey ,&nbsp;David Ullman ,&nbsp;Leon Su ,&nbsp;Chuying Su ,&nbsp;Chad Siniard ,&nbsp;Sierra Simmons ,&nbsp;Jesse Edberg ,&nbsp;Lance A. Williams III","doi":"10.1016/j.transci.2024.104001","DOIUrl":"10.1016/j.transci.2024.104001","url":null,"abstract":"<div><h3>Background</h3><p>Blood and plasma volume calculations are a daily part of practice for many Transfusion Medicine and Apheresis practitioners. Though many formulas exist, each facility may have their own modifications to consider. ChatGPT (Generative Pre-trained Transformer) provides a new and exciting pathway for those with no programming experience to create personalized programs to meet the demands of daily practice. Additionally, this pathway creates computer programs that provide accurate and reproducible outputs. Herein, we aimed to create a step-by-step process for clinicians to create customized computer programs for use in everyday practice.</p></div><div><h3>Methods</h3><p>We created a process of inputs to ChatGPT-4<sub>0</sub>, which generated computer programming code. This code was copied and pasted into Notepad (and saved as a Python file) and Google Colaboratory to verify functionality. We validated the durability of our process by repeating it over a 5-day timeframe and by recruiting volunteers to reproduce our outputs using the suggested process.</p></div><div><h3>Results</h3><p>Computer code generated by ChatGPT-4<sub>0</sub> in response to our common language inputs was accurate and durable over time. The code was fully functional in both Python and Colaboratory. Volunteers reproduced our process and outputs with minimal assistance.</p></div><div><h3>Conclusion</h3><p>We analyzed the practical application of ChatGPT-4<sub>0</sub> and artificial intelligence (AI) to perform daily calculations encountered in Transfusion Medicine. Our results provide a proof of concept that people with no programming experience can create customizable solutions for their own facilities. Our future work will expand to the creation of comprehensive and customizable websites designed for each individual user.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 6","pages":"Article 104001"},"PeriodicalIF":1.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study 严重 A 型血友病基因突变与产生抑制剂风险之间的关系:大型单中心研究
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-09-08 DOI: 10.1016/j.transci.2024.104002
Arash Ahmadfard Moghadam , Amir Reza Manafzadeh , MR Nikoonia , Seyedeh Somayeh Moazezi , Khadijeh Dajliry Nekoei , Farahnaz Ramezan , Davood Bashash , Mohsen Hamidpour , Shadi Tabibian

Background

One of the major problems for patients with severe hemophilia A (HA) is the development of neutralizing antibodies against factor VIII. This study aimed to analyze the molecular and clinical profiles of patients with severe HA and to determine if certain genetic variants predispose to inhibitor development in these patients.

Methods

A single-center study was conducted among patients with severe HA between March 20, 2000, and June 31, 2023. Demographic data and laboratory results of patients were collected. The inverse-shifting PCR (IS-PCR) technique was initially used to screen patients for intron 22 and 1 inversions (Inv-22 and Inv-1).

Results

A total of 480 patients with severe HA (408 without inhibitors and 72 with inhibitors) were enrolled in this study. The median age of the patients at the time of diagnosis was 6 months (IQR: 3 months to 18 months). Inv-22 was observed in 199 (41.5 %) of the cases. Among those patients who developed inhibitors, 53 (73.6 %) were classified as high-titer and 19 (26.4 %) as low-titer. Inv-22, positive family history of inhibitor formation, and history of intense injections revealed a statistically significant association with the risk of inhibitor development.

Conclusion

The results of this study confirm the important role of different genetic variants, family history of inhibitor formation, and history of intense injections for the formation of inhibitors in patients with severe HA. This would allow us to stratify the patients which can have important clinical implications, especially in terms of their management and outcome.

背景严重甲型血友病(HA)患者的主要问题之一是产生针对第八因子的中和抗体。本研究旨在分析重症甲型血友病患者的分子和临床特征,并确定某些基因变异是否会导致这些患者产生抑制剂。方法在 2000 年 3 月 20 日至 2023 年 6 月 31 日期间对重症甲型血友病患者进行了一项单中心研究。研究收集了患者的人口统计学数据和实验室结果。结果 共有 480 例重症 HA 患者(408 例未服用抑制剂,72 例服用抑制剂)参与了这项研究。患者确诊时的中位年龄为 6 个月(IQR:3 个月至 18 个月)。199例(41.5%)患者出现了Inv-22。在出现抑制的患者中,53 例(73.6%)被归类为高滴度,19 例(26.4%)被归类为低滴度。Inv-22、抑制剂形成的阳性家族史和高强度注射史与抑制剂形成的风险有显著的统计学关联。这将使我们能够对患者进行分层,从而产生重要的临床影响,尤其是在患者的管理和预后方面。
{"title":"Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study","authors":"Arash Ahmadfard Moghadam ,&nbsp;Amir Reza Manafzadeh ,&nbsp;MR Nikoonia ,&nbsp;Seyedeh Somayeh Moazezi ,&nbsp;Khadijeh Dajliry Nekoei ,&nbsp;Farahnaz Ramezan ,&nbsp;Davood Bashash ,&nbsp;Mohsen Hamidpour ,&nbsp;Shadi Tabibian","doi":"10.1016/j.transci.2024.104002","DOIUrl":"10.1016/j.transci.2024.104002","url":null,"abstract":"<div><h3>Background</h3><p>One of the major problems for patients with severe hemophilia A (HA) is the development of neutralizing antibodies against factor VIII. This study aimed to analyze the molecular and clinical profiles of patients with severe HA and to determine if certain genetic variants predispose to inhibitor development in these patients.</p></div><div><h3>Methods</h3><p>A single-center study was conducted among patients with severe HA between March 20, 2000, and June 31, 2023. Demographic data and laboratory results of patients were collected. The inverse-shifting PCR (IS-PCR) technique was initially used to screen patients for intron 22 and 1 inversions (Inv-22 and Inv-1).</p></div><div><h3>Results</h3><p>A total of 480 patients with severe HA (408 without inhibitors and 72 with inhibitors) were enrolled in this study. The median age of the patients at the time of diagnosis was 6 months (IQR: 3 months to 18 months). Inv-22 was observed in 199 (41.5 %) of the cases. Among those patients who developed inhibitors, 53 (73.6 %) were classified as high-titer and 19 (26.4 %) as low-titer. Inv-22, positive family history of inhibitor formation, and history of intense injections revealed a statistically significant association with the risk of inhibitor development.</p></div><div><h3>Conclusion</h3><p>The results of this study confirm the important role of different genetic variants, family history of inhibitor formation, and history of intense injections for the formation of inhibitors in patients with severe HA. This would allow us to stratify the patients which can have important clinical implications, especially in terms of their management and outcome.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 6","pages":"Article 104002"},"PeriodicalIF":1.4,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142171654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations regarding the potential resurgence of transfusion-transmitted syphilis in the United States due to increasing disease incidence and use of fresh blood products 关于美国因疾病发病率上升和使用新鲜血液产品而可能再次出现输血传播梅毒的考虑。
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-30 DOI: 10.1016/j.transci.2024.103993
Brian D. Adkins, Jordan Keith, Jeremy W. Jacobs, Garrett S. Booth
{"title":"Considerations regarding the potential resurgence of transfusion-transmitted syphilis in the United States due to increasing disease incidence and use of fresh blood products","authors":"Brian D. Adkins,&nbsp;Jordan Keith,&nbsp;Jeremy W. Jacobs,&nbsp;Garrett S. Booth","doi":"10.1016/j.transci.2024.103993","DOIUrl":"10.1016/j.transci.2024.103993","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 6","pages":"Article 103993"},"PeriodicalIF":1.4,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “ACKR1 gene polymorphisms in Bombay blood group (Oh) individuals of Indian origin” [Transfus Apher Sci 63 (2024) 103975] 印度裔孟买血型(Oh)个体的 ACKR1 基因多态性"[Transfus Apher Sci 63 (2024) 103975] 更正
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-23 DOI: 10.1016/j.transci.2024.103992
R. Shaikh, G. Kanjaksha, V. Kashivishwanath, S. Kulkarni, S. Jadhav, H. Maru, A. Gorakshakar
{"title":"Corrigendum to “ACKR1 gene polymorphisms in Bombay blood group (Oh) individuals of Indian origin” [Transfus Apher Sci 63 (2024) 103975]","authors":"R. Shaikh,&nbsp;G. Kanjaksha,&nbsp;V. Kashivishwanath,&nbsp;S. Kulkarni,&nbsp;S. Jadhav,&nbsp;H. Maru,&nbsp;A. Gorakshakar","doi":"10.1016/j.transci.2024.103992","DOIUrl":"10.1016/j.transci.2024.103992","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103992"},"PeriodicalIF":1.4,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1473050224001630/pdfft?md5=235bbdd6ae0a5d42189f83001ca74b70&pid=1-s2.0-S1473050224001630-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allogeneic serum-based eye drops may give better results than autologous drops in Sjögren's syndrome dry eye 在治疗斯约格伦综合征干眼症时,异体血清滴眼液可能比自体滴眼液效果更好
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-21 DOI: 10.1016/j.transci.2024.103991
Joanna Janus, Katarzyna Chmielewska, Jolanta Antoniewicz-Papis

Purpose

Sjögren’s syndrome (SS) may cause severe dry eye symptoms. One of the therapeutic option known for almost 40 years are autologous serum eye drops (ASEDs). Due to the presence of many pro-inflammatory factors in the autologous serum of SS patients, the use of allogeneic serum is often considered a better option. In our facility almost one-fifth of the patients using allogeneic serum-based eye drops (alloSEDs) suffered from autoimmune diseases, including SS. The study aim was to compare the effectiveness of both ASEDs and alloSEDs in SS patients.

Methods

From the group of SS patients using alloSEDs, five female SS patients aged 39–73 years were selected. They had the longest history of the use of the product. The analysis was based on OSDI forms and internal questionnaires which compared the effects of ASEDs and alloSEDs application. The patients used alloSEDs for a period of 5–28 months. All had previously used ASEDs for at least 2 years.

Results

For all five patients the mean OSDI after application of ASEDs and before introducing alloSEDs was 68.71, while the mean OSDI after the use of alloSEDs was 30.49.

Conclusion

In SS the treatment results are better with alloSEDs than with ASEDs. Almost all SS patients who applied both autologous and allogeneic drops reported better effects with the latter as also confirmed by the study cases.

目的 薛格伦综合征(SS)可能导致严重的干眼症状。自体血清滴眼液(ASEDs)是近 40 年来众所周知的治疗方法之一。由于 SS 患者的自体血清中存在许多促炎因子,使用异体血清通常被认为是更好的选择。在我院使用异体血清滴眼液(alloSEDs)的患者中,近五分之一患有自身免疫性疾病,包括 SS。研究目的是比较 ASED 和 alloSED 对 SS 患者的疗效。她们使用该产品的时间最长。分析以 OSDI 表格和内部问卷为基础,比较了 ASEDs 和 alloSEDs 的使用效果。患者使用 alloSEDs 的时间为 5-28 个月。结果在所有五名患者中,使用 ASEDs 后和引入 alloSEDs 前的平均 OSDI 为 68.71,而使用 alloSEDs 后的平均 OSDI 为 30.49。几乎所有同时使用自体和异体滴眼液的 SS 患者都表示使用异体滴眼液效果更好,研究病例也证实了这一点。
{"title":"Allogeneic serum-based eye drops may give better results than autologous drops in Sjögren's syndrome dry eye","authors":"Joanna Janus,&nbsp;Katarzyna Chmielewska,&nbsp;Jolanta Antoniewicz-Papis","doi":"10.1016/j.transci.2024.103991","DOIUrl":"10.1016/j.transci.2024.103991","url":null,"abstract":"<div><h3>Purpose</h3><p>Sjögren’s syndrome (SS) may cause severe dry eye symptoms. One of the therapeutic option known for almost 40 years are autologous serum eye drops (ASEDs). Due to the presence of many pro-inflammatory factors in the autologous serum of SS patients, the use of allogeneic serum is often considered a better option. In our facility almost one-fifth of the patients using allogeneic serum-based eye drops (alloSEDs) suffered from autoimmune diseases, including SS. The study aim was to compare the effectiveness of both ASEDs and alloSEDs in SS patients.</p></div><div><h3>Methods</h3><p>From the group of SS patients using alloSEDs, five female SS patients aged 39–73 years were selected. They had the longest history of the use of the product. The analysis was based on OSDI forms and internal questionnaires which compared the effects of ASEDs and alloSEDs application. The patients used alloSEDs for a period of 5–28 months. All had previously used ASEDs for at least 2 years.</p></div><div><h3>Results</h3><p>For all five patients the mean OSDI after application of ASEDs and before introducing alloSEDs was 68.71, while the mean OSDI after the use of alloSEDs was 30.49.</p></div><div><h3>Conclusion</h3><p>In SS the treatment results are better with alloSEDs than with ASEDs. Almost all SS patients who applied both autologous and allogeneic drops reported better effects with the latter as also confirmed by the study cases.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103991"},"PeriodicalIF":1.4,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of acute and chronic graft-versus-host disease with extracorporeal photopheresis: Update of best practice recommendations from Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO) 用体外射血疗法治疗急性和慢性移植物抗宿主病:意大利血液透析和细胞操作协会(SIdEM)和意大利骨髓移植、造血干细胞和细胞疗法移植小组(GITMO)的最佳实践建议更新版
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-13 DOI: 10.1016/j.transci.2024.103990
Anna Colpo , Monia Marchetti , Irene Bianco , Fabio Cruciani , Francesco Ipsevich , Mauro Montanari , Maria Teresa Lupo Stanghellini , on behalf of the Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO)

These guidelines represent a GRADE-method revision of the recommendations produced by the Italian Society of Hemapheresis and Cell Manipulation (SIDEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO) in 2013. Since 2013 several studies have been published that have strengthened the role of ECP in the management of GVHD. Thus, it was deemed appropriate to proceed with an update, with the aim to define uniform criteria for the application of ECP in adult and pediatric patients affected by GVHD throughout the national territory, in line with international guidelines, in maintaining of high standards of safety for patients and quality of the procedures provide. Post-HSCT GvHD therapies other than ECP and ECP therapy of other diseases, such as CTCL, are not covered by these guidelines.The development panel for this guideline includes professionals from various specialties who routinely interact in the management of the patient with GVHD, namely the transfusionist, the adult and pediatric hematologist, and the hospital pharmacist. A hematologist experienced in systematic reviews and GRADE guideline development ccordinated the development process, and an experienced transfusionist coordinated the assignment of tasks and reporting. External reviewers of the guideline included a patient representative.

这些指南是对意大利血液透析和细胞操作协会(SIDEM)和意大利骨髓移植、造血干细胞和细胞治疗移植小组(GITMO)于 2013 年提出的建议进行的 GRADE 方法修订。自 2013 年以来,已有多项研究证实了 ECP 在治疗 GVHD 中的作用。因此,我们认为有必要进行一次更新,目的是根据国际指南,在全国范围内为受 GVHD 影响的成人和儿童患者制定统一的 ECP 应用标准,以保持对患者安全的高标准和所提供程序的高质量。除 ECP 之外的 HSCT 后 GvHD 治疗方法和其他疾病(如 CTCL)的 ECP 治疗方法不在本指南范围内。本指南的制定小组成员包括来自各专科的专业人士,他们在治疗 GVHD 患者的过程中经常进行互动,即输血医师、成人和儿童血液科医师以及医院药剂师。一位在系统综述和 GRADE 指南制定方面经验丰富的血液科医生负责协调制定过程,一位经验丰富的输血科医生负责协调任务分配和报告工作。该指南的外部评审人员包括一名患者代表。
{"title":"Treatment of acute and chronic graft-versus-host disease with extracorporeal photopheresis: Update of best practice recommendations from Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO)","authors":"Anna Colpo ,&nbsp;Monia Marchetti ,&nbsp;Irene Bianco ,&nbsp;Fabio Cruciani ,&nbsp;Francesco Ipsevich ,&nbsp;Mauro Montanari ,&nbsp;Maria Teresa Lupo Stanghellini ,&nbsp;on behalf of the Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO)","doi":"10.1016/j.transci.2024.103990","DOIUrl":"10.1016/j.transci.2024.103990","url":null,"abstract":"<div><p>These guidelines represent a GRADE-method revision of the recommendations produced by the Italian Society of Hemapheresis and Cell Manipulation (SIDEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO) in 2013. Since 2013 several studies have been published that have strengthened the role of ECP in the management of GVHD. Thus, it was deemed appropriate to proceed with an update, with the aim to define uniform criteria for the application of ECP in adult and pediatric patients affected by GVHD throughout the national territory, in line with international guidelines, in maintaining of high standards of safety for patients and quality of the procedures provide. Post-HSCT GvHD therapies other than ECP and ECP therapy of other diseases, such as CTCL, are not covered by these guidelines.The development panel for this guideline includes professionals from various specialties who routinely interact in the management of the patient with GVHD, namely the transfusionist, the adult and pediatric hematologist, and the hospital pharmacist. A hematologist experienced in systematic reviews and GRADE guideline development ccordinated the development process, and an experienced transfusionist coordinated the assignment of tasks and reporting. External reviewers of the guideline included a patient representative.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103990"},"PeriodicalIF":1.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142087874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of continuous negative pressure suction combined with autologous platelet-rich gel on the levels of CRP, IL-6, wound healing and length of stay in clients with diabetic foot 持续负压吸引结合自体血小板丰富凝胶对糖尿病足患者 CRP、IL-6 水平、伤口愈合和住院时间的影响
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-10 DOI: 10.1016/j.transci.2024.103989
Lan Zhang , Yuan Zhao , Xiaoyun Fan, Dongliang Liu, Yan Geng

Objective

Continuous passive pressure suction and APG gel therapy effect diabetic foot IL-6, CRP, wound healing, and hospitalization.

Methods

Clinicopathological data from 102 diabetic foot ulcer patients treated at our institution between March 2018 and May 2022 was examined. Tables generated 51 joint and controlling teams randomly. The observation team received passive pressure suction and APG gel whereas the controlled team received conventional treatment. Teams monitored therapy outcomes, adverse responses, wound healing, hospital stay, and costs. Both teams compared blood uric acid, cystatin C, homocysteine, and serum IL-6, IL-10, and CRP before and after medication.

Results

The joint team had higher hospitalization costs, shorter stays, and faster wound healing than the controlled team. Diaparity was significant (P < 0.05). The united team worked 100 %, unlike the controlling team. This difference was significant (P < 0.05). Both teams showed significant decreases in CRP, IL-6, and IL-10 levels after therapy (P < 0.05). After therapy, both the combined and controlled teams had substantial differences in blood CRP, IL-6, and IL-10 levels (P < 0.05). Both teams had significantly decreased uric acid, cystatin C, and homocysteine after treatment. The combined team showed significantly decreased uric acid, cystatin C, homocysteine levels following therapy compared to the control team (P < 0.05).

Conclusion

The joint team experienced considerably fewer adverse events (3.92 % vs. 17.65 %) than the controls team (P < 0.05). Permanent passive pressure suction and APG gel therapy lower inflammatory response, blood uric acid, cystatin C, and homocysteine, speeding wound healing, reducing side effects.

目的连续被动压力吸引和APG凝胶治疗对糖尿病足IL-6、CRP、伤口愈合和住院治疗的影响。方法对2018年3月至2022年5月期间在我院接受治疗的102例糖尿病足溃疡患者的临床病理资料进行研究。表格随机生成51个联合组和对照组。观察组接受被动压力吸引和 APG 凝胶治疗,对照组接受常规治疗。各小组对治疗结果、不良反应、伤口愈合、住院时间和费用进行监测。两个小组比较了用药前后的血尿酸、胱抑素 C、同型半胱氨酸以及血清 IL-6、IL-10 和 CRP。差异显著(P < 0.05)。与对照组不同,联合小组的工作效率为 100%。这一差异非常明显(P < 0.05)。治疗后,两个团队的 CRP、IL-6 和 IL-10 水平都有明显下降(P < 0.05)。治疗后,联合组和对照组的血液 CRP、IL-6 和 IL-10 水平都有很大差异(P < 0.05)。治疗后,两组的尿酸、胱抑素 C 和同型半胱氨酸均明显下降。与对照组相比,联合治疗组治疗后尿酸、胱抑素 C 和同型半胱氨酸水平明显下降(P < 0.05)。永久性被动压力吸引和 APG 凝胶疗法可降低炎症反应、血尿酸、胱抑素 C 和同型半胱氨酸,加快伤口愈合,减少副作用。
{"title":"Effects of continuous negative pressure suction combined with autologous platelet-rich gel on the levels of CRP, IL-6, wound healing and length of stay in clients with diabetic foot","authors":"Lan Zhang ,&nbsp;Yuan Zhao ,&nbsp;Xiaoyun Fan,&nbsp;Dongliang Liu,&nbsp;Yan Geng","doi":"10.1016/j.transci.2024.103989","DOIUrl":"10.1016/j.transci.2024.103989","url":null,"abstract":"<div><h3>Objective</h3><p>Continuous passive pressure suction and APG gel therapy effect diabetic foot IL-6, CRP, wound healing, and hospitalization.</p></div><div><h3>Methods</h3><p>Clinicopathological data from 102 diabetic foot ulcer patients treated at our institution between March 2018 and May 2022 was examined. Tables generated 51 joint and controlling teams randomly. The observation team received passive pressure suction and APG gel whereas the controlled team received conventional treatment. Teams monitored therapy outcomes, adverse responses, wound healing, hospital stay, and costs. Both teams compared blood uric acid, cystatin C, homocysteine, and serum IL-6, IL-10, and CRP before and after medication.</p></div><div><h3>Results</h3><p>The joint team had higher hospitalization costs, shorter stays, and faster wound healing than the controlled team. Diaparity was significant (P &lt; 0.05). The united team worked 100 %, unlike the controlling team. This difference was significant (P &lt; 0.05). Both teams showed significant decreases in CRP, IL-6, and IL-10 levels after therapy (P &lt; 0.05). After therapy, both the combined and controlled teams had substantial differences in blood CRP, IL-6, and IL-10 levels (P &lt; 0.05). Both teams had significantly decreased uric acid, cystatin C, and homocysteine after treatment. The combined team showed significantly decreased uric acid, cystatin C, homocysteine levels following therapy compared to the control team (P &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>The joint team experienced considerably fewer adverse events (3.92 % vs. 17.65 %) than the controls team (P &lt; 0.05). Permanent passive pressure suction and APG gel therapy lower inflammatory response, blood uric acid, cystatin C, and homocysteine, speeding wound healing, reducing side effects.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103989"},"PeriodicalIF":1.4,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1473050224001605/pdfft?md5=d51a6d22580fffd15948e33e78b4063b&pid=1-s2.0-S1473050224001605-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Memoriam of Riccardo Saccardi (Careggi University Hospital, Florence), eminent hematologist and a remarkable innovator in the treatment of autoimmune diseases by means of novel methodologies in HSC transplantation 悼念里卡多-萨卡迪(Riccardo Saccardi,佛罗伦萨卡雷吉大学医院),杰出的血液病学家,通过造血干细胞移植新方法治疗自身免疫性疾病的杰出创新者
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-10 DOI: 10.1016/j.transci.2024.103985
Francesco Lanza
{"title":"In Memoriam of Riccardo Saccardi (Careggi University Hospital, Florence), eminent hematologist and a remarkable innovator in the treatment of autoimmune diseases by means of novel methodologies in HSC transplantation","authors":"Francesco Lanza","doi":"10.1016/j.transci.2024.103985","DOIUrl":"10.1016/j.transci.2024.103985","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103985"},"PeriodicalIF":1.4,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1473050224001563/pdfft?md5=f0c8df4dc0664650182bab6e1160337e&pid=1-s2.0-S1473050224001563-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141964633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial comment: Reflections on current position and future trends on Immunoglobulins therapy 编辑评论:对免疫球蛋白疗法现状和未来趋势的思考。
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-09 DOI: 10.1016/j.transci.2024.103986
Jerard Seghatchian
{"title":"Editorial comment: Reflections on current position and future trends on Immunoglobulins therapy","authors":"Jerard Seghatchian","doi":"10.1016/j.transci.2024.103986","DOIUrl":"10.1016/j.transci.2024.103986","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103986"},"PeriodicalIF":1.4,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Safe Blood Transfusion Self‐Efficacy Scale for nurses: Validity and reliability study 为护士编制安全输血自我效能量表:有效性和可靠性研究
IF 1.4 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-08 DOI: 10.1016/j.transci.2024.103984
Gülsüm Dülger , Gülten Karahan Okuroglu

Aim

The aim of the study is to develop a scale to measure nurses' self-efficacy levels regarding safe blood transfusion practice.

Methods

This study, applied in methodological design, was conducted in a public university hospital in Istanbul between March-April 2021. The sample included 372 nurses. A draft form consisting of 75 items was prepared. Content validity, construct validity, distinctiveness, internal consistency reliability, two-half test reliability, test-retest, and item analysis methods were used to determine the psychometric properties of the scale.

Results

The exploratory factor analysis showed that the scale had a four-factor structure that explained 71.36 % of the total variance. The factor loads of 49 items were found to vary between 0.50 and 0.92. The item-total correlations were found to be between 0.55 and 0.92. The Cronbach's alpha value for the whole scale was 0.96.

Conclusion

The results of the analysis show the items constituting Safe Blood and Blood Products Transfusion Self-Efficacy Scale have validity and reliability criteria that can measure the nurses' self-efficacy levels regarding safe blood transfusion practice.

本研究旨在开发一种量表,用于测量护士在安全输血实践方面的自我效能水平。样本包括 372 名护士。编写了一份由 75 个项目组成的表格草案。采用内容效度、建构效度、显著性、内部一致性信度、两次半测试信度、重测和项目分析等方法确定量表的心理测量属性。结果探索性因子分析显示,量表具有四因子结构,解释了总方差的 71.36%。49 个项目的因子载荷介于 0.50 和 0.92 之间。项目-总相关系数介于 0.55 和 0.92 之间。整个量表的 Cronbach's alpha 值为 0.96。结论分析结果表明,构成安全输血和输血产品自我效能感量表的项目具有有效性和可靠性标准,可以测量护士在安全输血实践方面的自我效能感水平。
{"title":"Development of Safe Blood Transfusion Self‐Efficacy Scale for nurses: Validity and reliability study","authors":"Gülsüm Dülger ,&nbsp;Gülten Karahan Okuroglu","doi":"10.1016/j.transci.2024.103984","DOIUrl":"10.1016/j.transci.2024.103984","url":null,"abstract":"<div><h3>Aim</h3><p>The aim of the study is to develop a scale to measure nurses' self-efficacy levels regarding safe blood transfusion practice.</p></div><div><h3>Methods</h3><p>This study, applied in methodological design, was conducted in a public university hospital in Istanbul between March-April 2021. The sample included 372 nurses. A draft form consisting of 75 items was prepared. Content validity, construct validity, distinctiveness, internal consistency reliability, two-half test reliability, test-retest, and item analysis methods were used to determine the psychometric properties of the scale.</p></div><div><h3>Results</h3><p>The exploratory factor analysis showed that the scale had a four-factor structure that explained 71.36 % of the total variance. The factor loads of 49 items were found to vary between 0.50 and 0.92. The item-total correlations were found to be between 0.55 and 0.92. The Cronbach's alpha value for the whole scale was 0.96.</p></div><div><h3>Conclusion</h3><p>The results of the analysis show the items constituting Safe Blood and Blood Products Transfusion Self-Efficacy Scale have validity and reliability criteria that can measure the nurses' self-efficacy levels regarding safe blood transfusion practice.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103984"},"PeriodicalIF":1.4,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Transfusion and Apheresis Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1